[go: up one dir, main page]

WO2000076500A3 - Compound for use as a medicament for treatment of disorders involving bronchocontraction - Google Patents

Compound for use as a medicament for treatment of disorders involving bronchocontraction Download PDF

Info

Publication number
WO2000076500A3
WO2000076500A3 PCT/SE2000/001267 SE0001267W WO0076500A3 WO 2000076500 A3 WO2000076500 A3 WO 2000076500A3 SE 0001267 W SE0001267 W SE 0001267W WO 0076500 A3 WO0076500 A3 WO 0076500A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
compound
treatment
disorders involving
bronchocontraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2000/001267
Other languages
English (en)
Other versions
WO2000076500A8 (fr
WO2000076500A2 (fr
Inventor
Staffan Skogvall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respiratorius AB
Original Assignee
Respiratorius AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902252A external-priority patent/SE9902252D0/xx
Priority claimed from SE9902251A external-priority patent/SE9902251D0/xx
Priority claimed from PCT/SE2000/000819 external-priority patent/WO2000064441A2/fr
Priority to JP2001502833A priority Critical patent/JP2003501462A/ja
Priority to AU58619/00A priority patent/AU5861900A/en
Priority to EP00944534A priority patent/EP1185263A2/fr
Application filed by Respiratorius AB filed Critical Respiratorius AB
Priority to AU2001225664A priority patent/AU2001225664A1/en
Priority to AU2001225663A priority patent/AU2001225663A1/en
Priority to PCT/SE2000/002612 priority patent/WO2001095902A1/fr
Priority to PCT/SE2000/002613 priority patent/WO2001095903A1/fr
Publication of WO2000076500A2 publication Critical patent/WO2000076500A2/fr
Publication of WO2000076500A3 publication Critical patent/WO2000076500A3/fr
Publication of WO2000076500A8 publication Critical patent/WO2000076500A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un composé qui présente une activité d'agoniste du récepteur 5-HT4 et qui est destiné à être utilisé comme médicament, l'utilisation dudit composé dans la fabrication d'un médicament destiné à être utilisé dans le cadre d'un traitement thérapeutique ou prophylactique de troubles impliquant une bronchoconstriction chez l'homme ou chez l'animal, et des méthodes de traitement basées sur l'administration desdits composés. La présente invention concerne également un composé qui présente une activité d'antagoniste du récepteur 5-HT3 et qui est destiné à être utilisé comme médicament, l'utilisation dudit composé dans la fabrication d'un médicament destiné à être utilisé dans le cadre d'un traitement thérapeutique ou prophylactique de troubles impliquant une bronchoconstriction chez l'homme ou chez l'animal, et des méthodes de traitement basées sur l'administration desdits composés.
PCT/SE2000/001267 1999-06-15 2000-06-15 Compound for use as a medicament for treatment of disorders involving bronchocontraction Ceased WO2000076500A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2001502833A JP2003501462A (ja) 1999-06-15 2000-06-15 受容体アゴニストおよびアンタゴニスト
AU58619/00A AU5861900A (en) 1999-06-15 2000-06-15 Receptor agonists and antagonists
EP00944534A EP1185263A2 (fr) 1999-06-15 2000-06-15 Agonistes et antagonistes de recepteurs
AU2001225664A AU2001225664A1 (en) 2000-06-15 2000-12-20 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
PCT/SE2000/002613 WO2001095903A1 (fr) 2000-06-15 2000-12-20 Antagonistes du recepteur 5-ht3 destines au traitement de troubles englobant la constriction des voies aeriennes
PCT/SE2000/002612 WO2001095902A1 (fr) 2000-06-15 2000-12-20 Composition contenant une association d'agonistes et d'antagonistes d'un recepteur
AU2001225663A AU2001225663A1 (en) 2000-06-15 2000-12-20 A composition comprising a combination of receptor agonists and antagonists

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
SE9902251-9 1999-06-15
SE9902252-7 1999-06-15
SE9902252A SE9902252D0 (sv) 1999-06-15 1999-06-15 Medicinskt preparat
SE9902251A SE9902251D0 (sv) 1999-06-15 1999-06-15 Medicinskt preparat
US13963299P 1999-06-17 1999-06-17
US13963399P 1999-06-17 1999-06-17
US60/139,633 1999-06-17
US60/139,632 1999-06-17
SEPCT/SE00/00819 2000-04-28
PCT/SE2000/000819 WO2000064441A2 (fr) 1999-04-28 2000-04-28 Medicament

Publications (3)

Publication Number Publication Date
WO2000076500A2 WO2000076500A2 (fr) 2000-12-21
WO2000076500A3 true WO2000076500A3 (fr) 2001-07-12
WO2000076500A8 WO2000076500A8 (fr) 2001-08-16

Family

ID=56290034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/001267 Ceased WO2000076500A2 (fr) 1999-06-15 2000-06-15 Compound for use as a medicament for treatment of disorders involving bronchocontraction

Country Status (5)

Country Link
EP (1) EP1185263A2 (fr)
JP (1) JP2003501462A (fr)
CN (1) CN1355698A (fr)
AU (1) AU5861900A (fr)
WO (1) WO2000076500A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918425D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
WO2001095903A1 (fr) * 2000-06-15 2001-12-20 Respiratorius Ab Antagonistes du recepteur 5-ht3 destines au traitement de troubles englobant la constriction des voies aeriennes
AU2002212888A1 (en) * 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
BR0312501A (pt) * 2002-07-10 2005-04-12 Warner Lambert Co Combinação de um inibidor alostérico ou metaloproteinase de matriz-13 com um inibidor de ciclooxigenase-2 diferente de celecoxib ou valdecoxib
US6986901B2 (en) 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
US7317022B2 (en) 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
GB0901487D0 (en) 2009-01-30 2009-03-11 Movetis N V Asthma Therapy
AU2016222550B2 (en) 2015-02-27 2020-07-16 Dechra Limited Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
CN114845717A (zh) * 2019-10-21 2022-08-02 剑桥认知有限公司 使用组合疗法的精神分裂症性障碍治疗

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004660A1 (fr) * 1987-11-14 1989-06-01 Beecham Group Plc Antagonistes recepteurs 5-ht3 de traitement de la toux et de la bronchoconstriction
SU1701320A1 (ru) * 1988-03-29 1991-12-30 Рижский Медицинский Институт Способ купировани приступа бронхиальной астмы
US5418241A (en) * 1992-09-28 1995-05-23 Synthelabo Piperidine derivatives, their preparation and their application in therapeutics
WO1997017345A1 (fr) * 1995-11-09 1997-05-15 Synthelabo Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3?

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004660A1 (fr) * 1987-11-14 1989-06-01 Beecham Group Plc Antagonistes recepteurs 5-ht3 de traitement de la toux et de la bronchoconstriction
SU1701320A1 (ru) * 1988-03-29 1991-12-30 Рижский Медицинский Институт Способ купировани приступа бронхиальной астмы
US5418241A (en) * 1992-09-28 1995-05-23 Synthelabo Piperidine derivatives, their preparation and their application in therapeutics
WO1997017345A1 (fr) * 1995-11-09 1997-05-15 Synthelabo Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3?

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BENOIT GENTIL ET AL.: "Droperidol prevents serotonin-induced bronchospasm in the guinea pig", ANESTH. ANALG., vol. 72, 1991, pages 612 - 615, XP002938846 *
D.T.T. CHUA ET AL.: "The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in orientals receiving cisplatin chemotherapy: a randomized crossover trial", BR. J. CLIN. PHARMACOL., vol. 41, 1996, pages 403 - 408, XP001006146 *
DATABASE CA [online] 17 August 1992 (1992-08-17), TAIVAN I.L. ET AL.: "Method for stopping bronochial asthma attack", XP002948473, accession no. STN Database accession no. 117:63015 *
ENRIQUE HONG ET AL.: "Similarities between the pharmacological actions of quipazine and serotonin", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 6, 1969, pages 274 - 280, XP002938849 *
F. GUERRIN ET AL.: "Effects du metoclopramide sur le bronchospasme experimental du cobaye et sur le test a l'acetylcholine chez l'homme", LILLE MEDICAL, vol. 16, no. 5, 1971, pages 731 - 735, XP002906226 *
J. SIMKE ET AL.: "Bradykinin induced bronchoconstriction in guinea pigs and its modification by various agents", ARCH. INT. PHARMACODYN., vol. 165, no. 2, 1967, pages 291 - 301, XP002906227 *
L.B. LIPHAM ET AL.: "Quipazine-metoclopramide inhibition of CB-154-induced prolactin suppression in rats: Neurotransmitter-metabolite correlations (42475)", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 184, 1987, pages 250 - 255, XP001062639 *
M.P. RECHTMAN ET AL.: "Effects of morphine, H-Tyr-D-Arg-Phe-Lys-NH2(DALDA) and B-HT920 on non-cholinergic nerve-mediated bronchoconstriction in pithed guinea-pigs", BR. J. PHARMACOL., vol. 101, 1990, pages 269 - 272, XP002938845 *
M.P. RECHTMAN: "Sensory nerves in the airways as a target for drug development", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 19, 1992, pages 31 - 39, XP002938844 *
N. OTOMO ET AL.: "In vivo assessment of droperidol-induced bronchial relaxation in dogs using a superfine fibreoptic bronchoscope", BRITISH JOURNAL OF ANAESTHESIA, vol. 78, 1997, pages 579 - 582, XP002938843 *
RICHARD A. STEINBROOK ET AL.: "Prophylactic antiemetics for laparoscopic cholecystectomy: a comparison of perphenazine, droperidol plus ondansetron and droperidol plus metoclopramide", JOURNAL OF CLINICAL ANESTHESIA, vol. 10, 1998, pages 494 - 498, XP001004443 *
SHAHIN SANJAR ET AL.: "The effect of prophylactic anti-asthma drugs on PAF-induced airway hyperreactivity", JAPAN. J. PHARMACOL., vol. 51, 1989, pages 151 - 160, XP002938847 *
T.J. HEMNANI & P.G. DASHPUTRA: "Potentiation of the psychotropic effect of chlorpromazine by metoclopramide", INDIAN J. MED. RES., vol. 78, October 1983 (1983-10-01), pages 593 - 595, XP002940951 *
VITTORIO GEBBIA ET AL.: "Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study", ANTI-CANCER DRUGS, vol. 7, 1996, pages 734 - 737, XP002938130 *
YOSHIO TSUCHIYA ET AL.: "Inhibition of the vagal reflex-induced tracheal constriction by psychotropic drugs", J. PHARMACOBIO-DYN., vol. 12, 1989, pages 437 - 440, XP002938848 *

Also Published As

Publication number Publication date
CN1355698A (zh) 2002-06-26
JP2003501462A (ja) 2003-01-14
WO2000076500A8 (fr) 2001-08-16
AU5861900A (en) 2001-01-02
WO2000076500A2 (fr) 2000-12-21
EP1185263A2 (fr) 2002-03-13

Similar Documents

Publication Publication Date Title
WO2000064441A3 (fr) Medicament
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
WO2003014309A3 (fr) Recepteurs de l'interleukine-1 dans le traitement de maladies
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
HK1038755A1 (zh) Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
WO1999017755A3 (fr) Medicaments
CA2375908A1 (fr) Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation
WO2001005763A3 (fr) Composes possedant une activite sur les recepteurs muscariniques
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
WO2004067002A3 (fr) Antagonistes selectifs du recepteur mglu5 destines au traitement de dysfonctionnements neuromusculaires du tractus urinaire inferieur
WO2004045593A3 (fr) Polytherapie anticancereuse au moyen d'un compose anticancereux active par gst et d'un autre traitement anticancereux
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2001001972A3 (fr) ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE
WO2002088100A3 (fr) 3-piperidinopropiophenones dopees et produits pharmaceutiques contenant ces composes
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
WO2004093881A3 (fr) Utilisation du dipyridamole ou du mopidamole pour le traitement et la prevention de maladies thrombo-emboliques et de troubles induits par la formation excessive de thrombine et/ou par l'expression elevee des recepteurs de la thrombine
WO2000076500A3 (fr) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EP1262197A3 (fr) Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil
HUP0200969A3 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders os mixed anxiety-depression disorders
TW200510420A (en) (1S, 5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3. 2. 0] heptane is an effective analgesic agent
WO2004026837A3 (fr) Antagonistes du recepteur h3 d'histamine, preparation et applications therapeutiques
SE9902597D0 (sv) New use
WO2002069944A3 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808979.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
ENP Entry into the national phase

Ref document number: 2001 502833

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000944534

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000944534

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10009559

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000944534

Country of ref document: EP